Limits...
Glucose-lowering effect of DLBS3233 is mediated through phosphorylation of tyrosine and upregulation of PPARγ and GLUT4 expression.

Tandrasasmita OM, Wulan DD, Nailufar F, Sinambela J, Tjandrawinata RR - Int J Gen Med (2011)

Bottom Line: DLBS3233 was also found to enhance the expression of genes associated with increased insulin signaling and sensitivity, such as peroxisome proliferator-activated receptor gamma, phosphatidylinositol-3 kinase, Akt, and glucose transporter 4.In addition, glucose transporter 4 protein levels were seen to increase as a result of DLBS3233 administration.DLBS3233, as a combination of herbal extracts, holds promise in the treatment of type 2 diabetes, and possibly also in prevention of the disease.

View Article: PubMed Central - PubMed

Affiliation: Division of Molecular Pharmacology.

ABSTRACT

Background: DLBS3233 is a standardized extract combination containing Lagerstroemia speciosa and Cinnamomum burmannii. The effect of DLBS3233 on glucose uptake, adiponectin secretion, and insulin signaling was examined in this study.

Methods: 3T3 Swiss albino preadipocytes and adipocytes were used to investigate gene expression detected using the reverse transcription polymerase chain reaction method. Immunoblotting assay and in vitro glucose uptake assay were also carried out in the experiment.

Results: DLBS3233 was seen to increase phosphorylation at the tyrosine residue of the insulin receptor substrate. DLBS3233 was also found to enhance the expression of genes associated with increased insulin signaling and sensitivity, such as peroxisome proliferator-activated receptor gamma, phosphatidylinositol-3 kinase, Akt, and glucose transporter 4. In addition, glucose transporter 4 protein levels were seen to increase as a result of DLBS3233 administration. The combination of extracts also increased glucose uptake and adiponectin secretion, and decreased resistin secretion significantly relative to control cells. Moreover, DLBS3233 administered to insulin-resistant Wistar rats showed an ability to control blood sugar, insulin levels, and other lipoproteins, including high-density lipoprotein, low-density lipoprotein, triglycerides, and total cholesterol.

Conclusion: DLBS3233, as a combination of herbal extracts, holds promise in the treatment of type 2 diabetes, and possibly also in prevention of the disease.

No MeSH data available.


Related in: MedlinePlus

Effect of DLBS3233 5 μg/mL on expression of tyrosine phosphorylation (A). The effect of DLBS3233 5 μg/mL and pioglitazone 0.02 μM in enhancing phosphatidylinositol-3 kinase (B) and Akt (C) gene expression in 3T3 Swiss albino preadipocytes. The effect of DLBS3233 1–5 μg/mL in enhancing glucose transporter 4 gene expression in 3T3 Swiss albino preadipocytes (D). Effect of DLBS3233 and pioglitazone with or without insulin in enhancing glucose transporter 4 gene expression (E), and also total glucose transporter 4 protein level (F).Notes: Results are mean value ± standard deviation of two independent experiments. *P < 0.05 indicates significant difference compared with controls.Abbreviation: AU, arbitrary unit.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3108202&req=5

f3-ijgm-4-345: Effect of DLBS3233 5 μg/mL on expression of tyrosine phosphorylation (A). The effect of DLBS3233 5 μg/mL and pioglitazone 0.02 μM in enhancing phosphatidylinositol-3 kinase (B) and Akt (C) gene expression in 3T3 Swiss albino preadipocytes. The effect of DLBS3233 1–5 μg/mL in enhancing glucose transporter 4 gene expression in 3T3 Swiss albino preadipocytes (D). Effect of DLBS3233 and pioglitazone with or without insulin in enhancing glucose transporter 4 gene expression (E), and also total glucose transporter 4 protein level (F).Notes: Results are mean value ± standard deviation of two independent experiments. *P < 0.05 indicates significant difference compared with controls.Abbreviation: AU, arbitrary unit.

Mentions: In this experiment, administration of DLBS3233 promoted tyrosine phosphorylation at the insulin receptor in a dose-dependent manner (Figure 3A). The concentration of DLBS3233 used in this experiment was in the range of 20–100 μg/mL. The administration of exogenous insulin (10 nM and 100 nM) also promotes tyrosine phosphorylation.


Glucose-lowering effect of DLBS3233 is mediated through phosphorylation of tyrosine and upregulation of PPARγ and GLUT4 expression.

Tandrasasmita OM, Wulan DD, Nailufar F, Sinambela J, Tjandrawinata RR - Int J Gen Med (2011)

Effect of DLBS3233 5 μg/mL on expression of tyrosine phosphorylation (A). The effect of DLBS3233 5 μg/mL and pioglitazone 0.02 μM in enhancing phosphatidylinositol-3 kinase (B) and Akt (C) gene expression in 3T3 Swiss albino preadipocytes. The effect of DLBS3233 1–5 μg/mL in enhancing glucose transporter 4 gene expression in 3T3 Swiss albino preadipocytes (D). Effect of DLBS3233 and pioglitazone with or without insulin in enhancing glucose transporter 4 gene expression (E), and also total glucose transporter 4 protein level (F).Notes: Results are mean value ± standard deviation of two independent experiments. *P < 0.05 indicates significant difference compared with controls.Abbreviation: AU, arbitrary unit.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3108202&req=5

f3-ijgm-4-345: Effect of DLBS3233 5 μg/mL on expression of tyrosine phosphorylation (A). The effect of DLBS3233 5 μg/mL and pioglitazone 0.02 μM in enhancing phosphatidylinositol-3 kinase (B) and Akt (C) gene expression in 3T3 Swiss albino preadipocytes. The effect of DLBS3233 1–5 μg/mL in enhancing glucose transporter 4 gene expression in 3T3 Swiss albino preadipocytes (D). Effect of DLBS3233 and pioglitazone with or without insulin in enhancing glucose transporter 4 gene expression (E), and also total glucose transporter 4 protein level (F).Notes: Results are mean value ± standard deviation of two independent experiments. *P < 0.05 indicates significant difference compared with controls.Abbreviation: AU, arbitrary unit.
Mentions: In this experiment, administration of DLBS3233 promoted tyrosine phosphorylation at the insulin receptor in a dose-dependent manner (Figure 3A). The concentration of DLBS3233 used in this experiment was in the range of 20–100 μg/mL. The administration of exogenous insulin (10 nM and 100 nM) also promotes tyrosine phosphorylation.

Bottom Line: DLBS3233 was also found to enhance the expression of genes associated with increased insulin signaling and sensitivity, such as peroxisome proliferator-activated receptor gamma, phosphatidylinositol-3 kinase, Akt, and glucose transporter 4.In addition, glucose transporter 4 protein levels were seen to increase as a result of DLBS3233 administration.DLBS3233, as a combination of herbal extracts, holds promise in the treatment of type 2 diabetes, and possibly also in prevention of the disease.

View Article: PubMed Central - PubMed

Affiliation: Division of Molecular Pharmacology.

ABSTRACT

Background: DLBS3233 is a standardized extract combination containing Lagerstroemia speciosa and Cinnamomum burmannii. The effect of DLBS3233 on glucose uptake, adiponectin secretion, and insulin signaling was examined in this study.

Methods: 3T3 Swiss albino preadipocytes and adipocytes were used to investigate gene expression detected using the reverse transcription polymerase chain reaction method. Immunoblotting assay and in vitro glucose uptake assay were also carried out in the experiment.

Results: DLBS3233 was seen to increase phosphorylation at the tyrosine residue of the insulin receptor substrate. DLBS3233 was also found to enhance the expression of genes associated with increased insulin signaling and sensitivity, such as peroxisome proliferator-activated receptor gamma, phosphatidylinositol-3 kinase, Akt, and glucose transporter 4. In addition, glucose transporter 4 protein levels were seen to increase as a result of DLBS3233 administration. The combination of extracts also increased glucose uptake and adiponectin secretion, and decreased resistin secretion significantly relative to control cells. Moreover, DLBS3233 administered to insulin-resistant Wistar rats showed an ability to control blood sugar, insulin levels, and other lipoproteins, including high-density lipoprotein, low-density lipoprotein, triglycerides, and total cholesterol.

Conclusion: DLBS3233, as a combination of herbal extracts, holds promise in the treatment of type 2 diabetes, and possibly also in prevention of the disease.

No MeSH data available.


Related in: MedlinePlus